Ventyx Biosciences (NASDAQ:VTYX) Given Neutral Rating at HC Wainwright

Ventyx Biosciences (NASDAQ:VTYXGet Free Report)‘s stock had its “neutral” rating reaffirmed by research analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $6.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 108.33% from the stock’s previous close.

A number of other equities analysts have also issued reports on the stock. Wells Fargo & Company upgraded shares of Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $7.00 to $16.00 in a research report on Tuesday, March 12th. Canaccord Genuity Group decreased their target price on shares of Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, March 13th. Oppenheimer decreased their target price on shares of Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Thursday, June 6th. Finally, Lifesci Capital upgraded shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research report on Wednesday, February 28th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Ventyx Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $15.75.

Check Out Our Latest Analysis on VTYX

Ventyx Biosciences Stock Up 0.3 %

VTYX stock opened at $2.88 on Thursday. Ventyx Biosciences has a fifty-two week low of $1.87 and a fifty-two week high of $40.58. The firm’s 50-day simple moving average is $4.36 and its 200 day simple moving average is $4.09. The stock has a market cap of $203.04 million, a PE ratio of -0.89 and a beta of 0.58.

Ventyx Biosciences (NASDAQ:VTYXGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. During the same quarter last year, the firm posted ($0.68) earnings per share. Equities analysts forecast that Ventyx Biosciences will post -2.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Ventyx Biosciences

Several large investors have recently made changes to their positions in VTYX. Swiss National Bank boosted its position in shares of Ventyx Biosciences by 9.5% during the 3rd quarter. Swiss National Bank now owns 90,200 shares of the company’s stock valued at $3,133,000 after purchasing an additional 7,800 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Ventyx Biosciences by 42.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 363,385 shares of the company’s stock valued at $12,620,000 after purchasing an additional 107,997 shares in the last quarter. Loomis Sayles & Co. L P boosted its position in shares of Ventyx Biosciences by 26.0% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,257,973 shares of the company’s stock valued at $43,689,000 after purchasing an additional 259,736 shares in the last quarter. Rafferty Asset Management LLC bought a new position in shares of Ventyx Biosciences during the 3rd quarter valued at about $209,000. Finally, FMR LLC boosted its holdings in shares of Ventyx Biosciences by 1.5% in the third quarter. FMR LLC now owns 8,677,529 shares of the company’s stock worth $301,371,000 after buying an additional 124,298 shares during the period. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

(Get Free Report)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

See Also

Analyst Recommendations for Ventyx Biosciences (NASDAQ:VTYX)

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.